nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
|
Raschi, Emanuel |
|
|
44 |
4 |
p. 505-506 |
artikel |
2 |
Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
|
Giugliano, Robert P. |
|
|
44 |
4 |
p. 503-504 |
artikel |
3 |
Communicating About Risks and Safe Use of Medicines
|
Edwards, I. Ralph |
|
|
44 |
4 |
p. 499-501 |
artikel |
4 |
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA
|
Weaver, James |
|
|
44 |
4 |
p. 479-497 |
artikel |
5 |
Correction to: Assessing the Safety of COVID-19 Vaccines: A Primer
|
Petousis-Harris, Helen |
|
|
44 |
4 |
p. 507 |
artikel |
6 |
Correction to: 19th ISoP Annual Meeting “New Opportunities for New Generations” Bogotá, Colombia, 26–29 October, 2019
|
|
|
|
44 |
4 |
p. 509 |
artikel |
7 |
Evaluation of the Risk of Inflammatory Bowel Disease after the HPV Vaccination in Primary Care in Spain: A Time-Varying Cohort Analysis of Around 390,000 Girls
|
Martín-Merino, Elisa |
|
|
44 |
4 |
p. 455-466 |
artikel |
8 |
French Pharmacovigilance Public System and COVID-19 Pandemic
|
Grandvuillemin, Aurélie |
|
|
44 |
4 |
p. 405-408 |
artikel |
9 |
ISoP Fellowships: Recognising and Promoting Leaders in Pharmacovigilance
|
McCarthy, Deirdre |
|
|
44 |
4 |
p. 403-404 |
artikel |
10 |
Provision and Need for Medicine Information in Asia and Africa: A Scoping Review of the Literature
|
Nualdaisri, Pitchaya |
|
|
44 |
4 |
p. 421-437 |
artikel |
11 |
Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015
|
Albogami, Yasser |
|
|
44 |
4 |
p. 447-454 |
artikel |
12 |
Risk Management for the 21st Century: Current Status and Future Needs
|
Mouchantaf, Rania |
|
|
44 |
4 |
p. 409-419 |
artikel |
13 |
Safety Consequences of Off-Label Drugs Used for COVID-19
|
Dasgupta, Nabarun |
|
|
44 |
4 |
p. 399-402 |
artikel |
14 |
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
|
FitzGerald, J. Mark |
|
|
44 |
4 |
p. 467-478 |
artikel |
15 |
The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years
|
Violari, Avy |
|
|
44 |
4 |
p. 439-446 |
artikel |